News & Updates

Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are aggressive forms of interstitial lung diseases (ILDs), characterized by ongoing fibrosis, progressive lung function decline, and early mortality. While current antifibrotics (nintedanib and pirfenidone) slow disease progression, there remains a need for therapies offering stronger disease control and improved survival. At the 2025 Autumn Respiratory Seminar in Hong Kong, Professor Philip Molyneaux of Imperial College London, UK, highlighted recent data on nondominant, a selective phosphodiesterase 4B (PDE4B) inhibitor that slows lung function decline and shows a reduced risk of death, representing a major advance in IPF and PPF. 

First-line treatment with immune checkpoint inhibitors (ICIs) is safe and effective in patients with extended stage (ES) small-cell lung cancer (SCLC), but its use as second-line agent is not recommended, according to a study.

Propofol-based anaesthesia does not improve cancer-related outcomes in patients undergoing surgical resection of malignancies in the GA-CARES* trial.

Patients with systemic autoimmune rheumatic disease (SARD)-associated interstitial lung disease (ILD) tend to live longer than those with idiopathic pulmonary fibrosis (IPF), reveals a study.

In lung cancer patients receiving immune checkpoint inhibitors (ICIs), survival is not necessarily better when treatment is administered in the morning vs in the afternoon, according to the i-TIMES study.

More than 80 percent of patients with long COVID have obstructive sleep apnoea (OSA), and these patients present with insomnia rather than the classic excessive daytime sleepiness, according to new research.

Borderline personality disorder (BPD) is associated with higher risks of a wide range of physical diseases and increased mortality from all causes, natural causes, and external causes, according to a 16-year population-based cohort study in Hong Kong.